Abstract: Objective To analyze the predictive value of α-Hydroxybutyrate dehydrogenase (α-HBDH) combined detection soluble E-cadherin (SE-CAD) levels for chemotherapy prognosis in patients with acute myeloid leukemia (AML). Methods A total of 86 patients with AML admitted to the First Affiliated Hospital of Henan University of Science and Technology from January 2021 to June 2023 were selected as the study group, and another 86 healthy individuals who underwent physical examinations during the same period were selected as the control group. After three cycles of decitabine treatment, patients with AML were divided into complete remission (n=28), partial remission (n=37) and non remission (n=21), and patients were divided into good prognosis (n=65) and poor prognosis (n=21) followed up for 9 months. The levels of serum α-HBDH and SE-CAD were compared in patients with different treatment outcomes and prognosis at admission between the two groups. The predictive value of combined detection of serum α-HBDH and SE-CAD levels on the prognosis of AML patients undergoing chemotherapy was analyzed using receiver operating characteristic (ROC) analysis. Results The levels of serum α-HBDH and SE-CAD in the study group were significantly higher than those in the control group at admission (P<0.05). Upon admission, the levels of serum α-HBDH and SE-CAD were compared, with complete remission < partial remission < no remission (P<0.05). The levels of serum α-HBDH and SE-CAD in patients with poor prognosis were significantly higher than those in patients with good prognosis at admission (P<0.05). The area under the curve (AUC) of serum α-HBDH and SE-CAD levels alone and in combination for predicting poor prognosis at admission were 0.642, 0.674, and 0.777, respectively. The combined detection of the two indicators was significantly higher than the detection of each indicator alone. Conclusion The levels of serum α-HBDH and SE-CAD are correlated with the clinical efficacy and prognosis of patients with AML. The detection of their levels have a certain guiding role in the clinical evaluation of the efficacy and prognosis of patients, and can be applied as an auxiliary index for the prognosis evaluation of AML.

Key words: α-Hydroxybutyrate dehydrogenase, Soluble E-cadherin, Acute myeloid leukemia, Chemotherapy prognosis

摘要： 目的 分析血清α羟丁酸脱氢酶（α-HBDH）、可溶性E钙粘蛋白（SE-CAD）水平联合检测对急性髓系白血病（AML）患者化疗预后的预测价值。方法 选取河南科技大学第一附属医院2021年1月~2023年6月收治的86例AML患者为研究组,另选取同期86名健康体检者为对照组。AML患者通过地西他滨治疗3个周期后,评估患者临床疗效分为完全缓解（n=28）、部分缓解（n=37）和未缓解（n=21）,并进行为期9个月的随访观察,分为预后良好患者（n=65）及预后不良患者（n=21）。对比2组及不同床疗效及预后患者入院时血清α-HBDH、SE-CAD水平,采用接受者操作特性（ROC）分析入院时血清α-HBDH、SE-CAD水平联合检测对AML患者化疗预后的预测价值。结果 研究组入院时血清α-HBDH、SE-CAD水平显著高于对照组（P<0.05）;入院时血清α-HBDH、SE-CAD水平比较,完全缓解<部分缓解<未缓解（P<0.05）;预后不良患者入院时血清α-HBDH、SE-CAD水平显著高于预后良好患者（P<0.05）;入院时血清α-HBDH、SE-CAD水平单独及联合预测预后不良的曲线下面积（AUC）分别为0.642、0.674、0777,二者联合检测显著高于各指标单独检测。结论 血清α-HBDH、SE-CAD水平与AML患者临床疗效及预后相关,通过检测其水平对临床评估患者疗效及预后具有一定指导作用,可作为AML预后评估的辅助指标。

关键词: α羟丁酸脱氢酶, 可溶性E钙粘蛋白, 急性髓系白血病, 化疗预后